EcoDrugPlus

24-Dehydrocholesterol Reductase

Ensembl ID : ENSACIG00000013449
Gene Symbol: DHCR24
1 Cross references
209 Possible Orthologues:

3-Hydroxy-3-Methylglutaryl-Coa Reductase

Ensembl ID : ENSACIG00000007426
Gene Symbol: HMGCR
1 Cross references
194 Possible Orthologues:

3-Hydroxy-3-Methylglutaryl-Coa Reductase B

Ensembl ID : ENSACIG00000006291
Gene Symbol: HMGCRB
1 Cross references
206 Possible Orthologues:

3-Phosphoinositide Dependent Protein Kinase 1b

Ensembl ID : ENSACIG00000022875
Gene Symbol: PDPK1B
1 Cross references
222 Possible Orthologues:

4-Hydroxyphenylpyruvate Dioxygenase B

Ensembl ID : ENSACIG00000020581
Gene Symbol: HPDB
1 Cross references
207 Possible Orthologues:

5'-Nucleotidase Ecto

Ensembl ID : ENSACIG00000002342
Gene Symbol: NT5E
1 Cross references
190 Possible Orthologues:

5'-Nucleotidase, Ecto (Cd73)

Ensembl ID : ENSACIG00000023576
Gene Symbol: NT5E
2 Cross references
194 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 1a B

Ensembl ID : ENSACIG00000009652
Gene Symbol: HTR1AB
1 Cross references
138 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 2b, G Protein-Coupled

Ensembl ID : ENSACIG00000012866
Gene Symbol: HTR2B
1 Cross references
203 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 2c, G Protein-Coupled-Like 1

Ensembl ID : ENSACIG00000007515
Gene Symbol: HTR2CL1
1 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 5a, Genome Duplicate B

Ensembl ID : ENSACIG00000018260
Gene Symbol: HTR5AB
1 Cross references
215 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSACIG00000023480
Gene Symbol: HTR1B
1 Cross references
180 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).